This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nieto, Y. Articles by Bearman, S. I. Search for Related Content PubMed PubMed Citation Articles by Nieto, Y. Articles by Bearman, S. I. Pubmed/NCBI databases Medline Plus Health Information Breast Cancer Social Bookmarking                            What's this?

Prognostic Model for Relapse After High-Dose Chemotherapy With Autologous Stem-Cell Transplantation for Stage IV Oligometastatic Breast Cancer

From the University of Colorado Bone Marrow Transplant Program and Departments of Pathology and Biostatistics, University of Colorado, Denver, CO.

Address reprint requests to Yago Nieto, MD, University of Colorado Health Sciences Center, 4200 E 9th Ave, B-190, Denver, CO 80262; email: yago.nieto{at}uchsc.edu

PURPOSE: To study prognostic factors after high-dose chemotherapy (HDC) for patients with stage IV oligometastatic breast cancer.

PATIENTS AND METHODS: Sixty patients with minimal metastatic disease amenable to local therapy enrolled onto a prospective HDC trial were analyzed for potential prognostic factors. Tumor blocks were retrospectively collected from referring institutions.

RESULTS: Median follow-up was 62 months (range, 4 to 120 months). Median relapse-free survival (RFS) and overall survival (OS) times were 52 and 80 months, respectively. Five-year RFS and OS rates were 52% (95% confidence interval [CI], 39% to 64%) and 62% (95% CI, 49% to 74%), respectively. HER-2 expression, number of tumor sites, primary axillary nodal ratio (number of positive nodes divided by number of sampled nodes), number of positive axillary nodes, and delivery or omission of radiotherapy to metastases correlated with RFS. HER-2 overexpression and more than one site were independent adverse risk factors for RFS. HER-2 and the axillary nodal ratio were independent predictors of OS. The following prognostic categories for RFS were established (RFS rate, median RFS): good risk, no factors (77%, 80 months); intermediate risk, one factor (41%, 28 months); and poor risk, both factors (10%, 10 months).

CONCLUSION: Long-term results in patients with oligometastatic breast cancer are encouraging but need validation in prospective randomized studies. HER-2 expression, number of sites, and primary nodal ratio are independent outcome predictors. Confirmation of these observations in this selected population would imply the need for reevaluation of the current tenet that early detection of metastatic breast cancer recurrence is of no benefit.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				W. J. Gradishar, J. R. Bellon, M. A. Gadd, H. A. D'Alessandro, and K. Braaten Case 30-2008 -- A 47-Year-Old Woman with a Mass in the Breast and a Solitary Lesion in the Spine N. Engl. J. Med., September 25, 2008; 359(13): 1382 - 1391. [Full Text] [PDF]

				R. Sposto, W. B. London, and T. A. Alonzo Criteria for Optimizing Prognostic Risk Groups in Pediatric Cancer: Analysis of Data From the Children's Oncology Group J. Clin. Oncol., May 20, 2007; 25(15): 2070 - 2077. [Abstract] [Full Text] [PDF]

				D. Rades, T. Veninga, L. J.A. Stalpers, H. Basic, V. Rudat, J. H. Karstens, J. Dunst, and S. E. Schild Outcome After Radiotherapy Alone for Metastatic Spinal Cord Compression in Patients With Oligometastases J. Clin. Oncol., January 1, 2007; 25(1): 50 - 56. [Abstract] [Full Text] [PDF]

				N. Kroger, M. Frick, O. Gluz, S. Mohrmann, B. Metzner, C. Jackisch, Y. Ko, H.-W. Lindemann, C. R. Meier, H. P. Lohrmann, et al. Randomized Trial of Single Compared With Tandem High-Dose Chemotherapy Followed by Autologous Stem-Cell Transplantation in Patients With Chemotherapy-Sensitive Metastatic Breast Cancer J. Clin. Oncol., August 20, 2006; 24(24): 3919 - 3926. [Abstract] [Full Text] [PDF]

				W. A. Woodward, V. Vinh-Hung, N. T. Ueno, Y. C. Cheng, M. Royce, P. Tai, G. Vlastos, A. M. Wallace, G. N. Hortobagyi, and Y. Nieto Prognostic Value of Nodal Ratios in Node-Positive Breast Cancer J. Clin. Oncol., June 20, 2006; 24(18): 2910 - 2916. [Abstract] [Full Text] [PDF]

				M. Morrow and L. Goldstein Surgery of the Primary Tumor in Metastatic Breast Cancer: Closing the Barn Door After the Horse Has Bolted? J. Clin. Oncol., June 20, 2006; 24(18): 2694 - 2696. [Full Text] [PDF]

				S. Rodenhuis, M. Bontenbal, Q. G. C. M. van Hoesel, W. M. Smit, M. A. Nooij, E. E. Voest, E. van der Wall, P. Hupperets, H. van Tinteren, J. L. Peterse, et al. Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer Ann. Onc., April 1, 2006; 17(4): 588 - 596. [Abstract] [Full Text] [PDF]

				Y. Nieto, J. J. Vredenburgh, E. J. Shpall, S. I. Bearman, P. A. McSweeney, N. Chao, D. Rizzieri, C. Gasparetto, S. Matthes, A. E. Baron, et al. Phase II Feasibility and Pharmacokinetic Study of Concurrent Administration of Trastuzumab and High-Dose Chemotherapy in Advanced HER2+ Breast Cancer Clin. Cancer Res., November 1, 2004; 10(21): 7136 - 7143. [Abstract] [Full Text] [PDF]

				C. Bernard-Marty, F. Cardoso, and M. J. Piccart Facts and Controversies in Systemic Treatment of Metastatic Breast Cancer Oncologist, November 1, 2004; 9(6): 617 - 632. [Abstract] [Full Text] [PDF]

				V. J. Assikis, K.-A. Do, S. Wen, X. Wang, J. H. Cho-Vega, S. Brisbay, R. Lopez, C. J. Logothetis, P. Troncoso, C. N. Papandreou, et al. Clinical and Biomarker Correlates of Androgen-Independent, Locally Aggressive Prostate Cancer with Limited Metastatic Potential Clin. Cancer Res., October 15, 2004; 10(20): 6770 - 6778. [Abstract] [Full Text] [PDF]

				Y. Nieto, E. J. Shpall, I. K. McNiece, S. Nawaz, J. Beaudet, S. Rosinski, J. Pellom, V. Slat-Vasquez, P. A. McSweeney, S. I. Bearman, et al. Prognostic Analysis of Early Lymphocyte Recovery in Patients with Advanced Breast Cancer Receiving High-Dose Chemotherapy with an Autologous Hematopoietic Progenitor Cell Transplant Clin. Cancer Res., August 1, 2004; 10(15): 5076 - 5086. [Abstract] [Full Text] [PDF]

				Y. Nieto, S. Nawaz, E. J. Shpall, S. I. Bearman, J. Murphy, and R. B. Jones Long-Term Analysis and Prospective Validation of a Prognostic Model for Patients with High-Risk Primary Breast Cancer Receiving High-Dose Chemotherapy Clin. Cancer Res., April 15, 2004; 10(8): 2609 - 2617. [Abstract] [Full Text] [PDF]

				P. J. Wild, A. Reichle, R. Andreesen, G. Rockelein, W. Dietmaier, J. Ruschoff, H. Blaszyk, F. Hofstadter, and A. Hartmann Microsatellite Instability Predicts Poor Short-Term Survival in Patients with Advanced Breast Cancer after High-Dose Chemotherapy and Autologous Stem-Cell Transplantation Clin. Cancer Res., January 15, 2004; 10(2): 556 - 564. [Abstract] [Full Text] [PDF]

				S. Rodenhuis, M. Bontenbal, L. V.A.M. Beex, J. Wagstaff, D. J. Richel, M. A. Nooij, E. E. Voest, P. Hupperets, H. van Tinteren, H. L. Peterse, et al. High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for High-Risk Breast Cancer N. Engl. J. Med., July 3, 2003; 349(1): 7 - 16. [Abstract] [Full Text] [PDF]

				S. E. Singletary, G. Walsh, J.-N. Vauthey, S. Curley, R. Sawaya, K. L. Weber, F. Meric, and G. N. Hortobagyi A Role for Curative Surgery in the Treatment of Selected Patients with Metastatic Breast Cancer Oncologist, June 1, 2003; 8(3): 241 - 251. [Abstract] [Full Text] [PDF]

				L. Gianni High-dose chemotherapy for breast cancer: any use for it? Ann. Onc., May 1, 2002; 13(5): 650 - 652. [Full Text] [PDF]

				G. N. Hortobagyi Can We Cure Limited Metastatic Breast Cancer? J. Clin. Oncol., February 1, 2002; 20(3): 620 - 623. [Full Text] [PDF]